Inclusion Criteria:  Patients with acute leukemia (AL) or myelodysplastic syndrome (MDS) who receive haploid allogeneic hematopoietic stem cell transplantation, pre-transplantation assessment ≤CR2; Age 18-60, including boundary value, gender unlimited; Refractory CMV infection occurred in the early stage of transplantation : After 2 weeks of standard antiviral treatment, the CMV DNA copy number continued to be ≥1000 copies/mL, and the CMV DNA copy number at the beginning of the treatment decreased by <log10 ； The transplant donor's HLA-A matching is one of 2402, 0201 or 1101, and the physical examination is qualified; ECOG ≤ 3, estimated life expectancy> 3 months; Patients who voluntarily sign informed consent and are willing to comply with treatment plans, visit arrangements, laboratory tests and other research procedures.  Exclusion Criteria:  Patients with active aGVHD III-IV and / or mild and severe cGVHD; Have received cell therapy such as DLI, CTL, CAR-T, NK or participated in any other clinical research on drugs and medical devices; Patients who have developed CMV disease;  patients with organ failure:  Heart: NYHA heart function grade IV; Liver: Grade C that achieves Child-Turcotte liver function grading; Kidney: kidney failure and uremia; Lung: symptoms of respiratory failure; Brain: a person with a disability; Pregnant or lactating women; The researchers found that it was unsuitable for the recipients to be enrolled.